Ascendis Pharma, Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Palo Alto CA United States (2006)

Organization Overview

First Clinical Trial
2009
NCT01010425
First Marketed Drug
2021
lonapegsomatropin (Skytrofa)
First NDA Approval
2021
lonapegsomatropin (Skytrofa)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Ascendis Pharma | Ascendis Pharma A/S | Ascendis Pharma A/S European Medical Monitor/Medical Expert | Ascendis Pharma A/S North American Medical Monitor/Medical Expert | Ascendis Pharma Bone Diseases A/S | ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S | Ascendis Pharma Endocrinology Division A/S | Ascendis Pharma Growth Disorders A/S | Ascendis Pharma Inc. | Ascendis Pharma, Inc. | Ascendis Pharma Oncology Division A/S

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Achondroplasia (Phase 2)

Dwarfism, Pituitary (Phase 3)

Endocrine System Diseases (Phase 3)

Hypoparathyroidism (Phase 2)

Parathyroid Diseases (Phase 2)

Pituitary Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 22
  • # of Trial APIs: 14